Yıl: 2021 Cilt: 32 Sayı: 9 Sayfa Aralığı: 720 - 726 Metin Dili: İngilizce DOI: 10.5152/tjg.2021.20832 İndeks Tarihi: 01-06-2022

Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer

Öz:
Background: Gastric cancer (GC) is a common cause of cancer-related deaths. The poor clinical outcome in GC patients is partially associated with a lack of appropriate diagnostic and prognostic biomarkers. In the present study, we evaluated the diagnostic and prognostic values of cell-free DNA (cfDNA) integrity and the concentration of circulating nucleosomes (cNUCs). Methods: In the study, 40 GC patients and 55 GC-free individuals were enrolled. Cell-free DNA integrity was calculated as the ratio of concentration of the longer ACTB (beta-actin) gene fragment to that of the shorter ACTB fragment, measured using quantitative PCR. Circulating nucleosomes were measured by an ELISA-based approach. Results: We found that cfDNA integrity is higher in GC patients than in the control subjects (relative median values 0.51 vs. 0.38, respectively, P = .56) indicating prominent abundance of longer fragments in the patients. The patients with larger tumors (T3-4) had significantly higher cfDNA integrity than those with T1-T2 tumors. We also found GC patients to have higher concentrations of cNUCs in their plasma (relative median values 3.64 vs. 3.1). Importantly, the patients with high cfDNA integrity (i.e., lower fragmentation) had longer overall survival rates at 3 years than those with lower cfDNA integrity (76.5% vs. 38.9%, P = .02). Conclusion: Cell-free DNA fragmentation has a prognostic value. However, it has no diagnostic value in GC.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Agostini M, Pucciarelli S, Enzo MV, et al. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann Surg Oncol. 2011;18(9):2461-2468. [CrossRef]
  • 2. Arko-Boham B, Aryee NA, Blay RM, et al. Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers. Cancer Genet. 2019;235-236:65-71. [CrossRef]
  • 3. Barták BK, Márkus E, Kalmár A, et al. Characteristics and diagnostic applications of circulating cell-free DNA in colorectal cancer. Orv Hetil. 2019;160(30):1167-1177. [CrossRef]
  • 4. Beranek M, Fiala Z, Kremlacek J, et al. Changes in circulating cellfree DNA and nucleosomes in patients with exacerbated psoriasis. Arch Dermatol Res. 2017;309(10):815-821. [CrossRef]
  • 5. Cao G, Xie Y, Jiang X, et al. Serum cell-free DNA concentrations and integrity analysis of colorectal cancer patients before and after surgery. Cell Mol Biol. 2019;65(6):44-51. [CrossRef]
  • 6. Deligezer U, Eralp Y, Akisik EE, et al. Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy. Clin Chem Lab Med. 2008;46(3):311-317. [CrossRef]
  • 7. Deng J, You Q, Gao Y, et al. Prognostic value of perineural invasion in gastric cancer: a systematic review and meta-analysis. PLoS One. 2014;9(2):e88907. [CrossRef]
  • 8. El Messaoudi SE, Mouliere F, Du Manoir S, et al. Circulating DNA as a strong multimarker prognostic tool for metastatic colorectal cancer patient management care. Clin Cancer Res. 2016;22(12):3067- 3077. [CrossRef]
  • 9. El-Gayar D, El-Abd N, Hassan N, Ali R. Increased free circulating DNA integrity index as a serum biomarker in patients with colorectal carcinoma. Asian Pac J Cancer Prev. 2016;17(3):939-944. [CrossRef]
  • 10. Elshimali YI, Khaddour H, Sarkissyan M, Wu Y, Vadgama JV. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. 2013;14(9):18925-18958. [CrossRef]
  • 11. Fahmueller YN, Nagel D, Hoffmann RT, et al. Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal radiation therapy. BMC Cancer. 2012;12:5. [CrossRef].
  • 12. Fawzy A, Sweify KM, El-Fayoumy HM, Nofal N. Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence. J Egypt Natl Canc Inst. 2016;28(4):235-242. [CrossRef].
  • 13. Fleischhacker M, Schmidt B, Weickmann S, et al. Methods for isolation of cell-free plasma DNA strongly affect DNA yield. Clin Chim Acta. 2011;412(23-24):2085-2088. [CrossRef].
  • 14. Holdenrieder S, Nagel D, Schalhorn A, et al. Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci. 2008;1137:180- 189. [CrossRef].
  • 15. Holdenrieder S, Stieber P. Therapy control in oncology by circulating nucleosomes. Ann N Y Acad Sci. 2004;1022:211-216. [CrossRef].
  • 16. Holdenrieder S, Stieber P, Bodenmüller H, et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer. 2001;95(2):114-120. [CrossRef].
  • 17. Huang A, Zhang X, Zhou SL, et al. Plasma circulating cell-free DNA integrity as a promising biomarker for diagnosis and surveillance in patients with hepatocellular carcinoma. J Cancer. 2016;7(13):1798-1803. [CrossRef].
  • 18. Iqbal S, Vishnubhatla S, Raina V, et al. Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer. Springerplus. 2015;17(4):265.
  • 19. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. [CrossRef]
  • 20. Kitahara M, Hazama S, Tsunedomi R, et al. Prediction of the efficacy of immunotherapy by measuring the integrity of cell-free DNA in plasma in colorectal cancer. Cancer Sci. 2016;107(12):1825-1829. [CrossRef]
  • 21. Kustanovich A, Schwartz R, Peretz T, Grinshpun A. Life and death of circulating cell-free DNA. Cancer Biol Ther. 2019;20(8):1057-1067. [CrossRef]
  • 22. Lam WKJ, Jiang P, Chan KCA, et al. Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases. Nat Commun. 2019;10(1):3256. [CrossRef]
  • 23. Leszinski G, Lehner J, Gezer U, Holdenrieder S. Increased DNA integrity in colorectal cancer. In Vivo. 2014;28(3):299-303.
  • 24. Li M, Jia Y, Xu J, Cheng X, Xu C. Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: a single-center experience. Ann Hematol. 2017;96(8):1343-1351. [CrossRef]
  • 25. Lu H, Busch J, Jung M, et al. Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients.Clin Chim Acta. 2016;452:109-119. [CrossRef]
  • 26. Moss J, Magenheim J, Neiman D, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun. 2018;9(1):5068. [CrossRef]
  • 27. Mouliere F, Robert B, Arnau Peyrotte E, et al. High fragmentation characterizes tumor-derived circulating DNA. PLoS One. 2011;6(9):e23418. [CrossRef]
  • 28. Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia. 2015;3:83-92. [CrossRef]
  • 29. Sai S, Ichikawa D, Tomita H, et al. Quantification of plasma cellfree DNA in patients with gastric cancer. Anticancer Res. 2007;27(4C):2747-2751.
  • 30. Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer pateints. Nat Rev Cancer. 2011;11(6):426- 437. [CrossRef]
  • 31. Schwarzenbach H, Stoehlmacher J, Pantel K, Goekkurt E. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci. 2008;1137:190-196. [CrossRef]
  • 32. Soliman SE, Alhanafy AM, Habib MSE, Hagag M, Ibrahem RAL. Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non small cell lung cancer. Biochem Biophys Rep. 2018;15(15):45-51. [CrossRef]
  • 33. Thakur S, Tobey A, Daley B, et al. Limited utility of circulating cell-free DNA integrity as a diagnostic tool for differentiating Between malignant and benign thyroid nodules with indeterminate cytology (Bethesda Category III). Front Oncol. 2019;9:905. [CrossRef]
  • 34. Yörüker EE, Özgür E, Keskin M, et al. Assessment of circulating serum DNA integrity in colorectal cancer patients. Anticancer Res. 2015;35(4):2435-2440.
  • 35. Zhang X, Wu Z, Shen Q, et al. Clinical significance of cell-free DNA concentration and integrity in serum of gastric cancer patients before and after surgery. Cell Mol Biol. 2019;65(7):111-117. [CrossRef]
APA Yoruker E, Özgür E, Keskin M, Ozgur I, Gezer U (2021). Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer. , 720 - 726. 10.5152/tjg.2021.20832
Chicago Yoruker Ebru Esin,Özgür Emre,Keskin Metin,Ozgur Ilker,Gezer Ugur Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer. (2021): 720 - 726. 10.5152/tjg.2021.20832
MLA Yoruker Ebru Esin,Özgür Emre,Keskin Metin,Ozgur Ilker,Gezer Ugur Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer. , 2021, ss.720 - 726. 10.5152/tjg.2021.20832
AMA Yoruker E,Özgür E,Keskin M,Ozgur I,Gezer U Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer. . 2021; 720 - 726. 10.5152/tjg.2021.20832
Vancouver Yoruker E,Özgür E,Keskin M,Ozgur I,Gezer U Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer. . 2021; 720 - 726. 10.5152/tjg.2021.20832
IEEE Yoruker E,Özgür E,Keskin M,Ozgur I,Gezer U "Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer." , ss.720 - 726, 2021. 10.5152/tjg.2021.20832
ISNAD Yoruker, Ebru Esin vd. "Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer". (2021), 720-726. https://doi.org/10.5152/tjg.2021.20832
APA Yoruker E, Özgür E, Keskin M, Ozgur I, Gezer U (2021). Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer. Turkish Journal of Gastroenterology, 32(9), 720 - 726. 10.5152/tjg.2021.20832
Chicago Yoruker Ebru Esin,Özgür Emre,Keskin Metin,Ozgur Ilker,Gezer Ugur Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer. Turkish Journal of Gastroenterology 32, no.9 (2021): 720 - 726. 10.5152/tjg.2021.20832
MLA Yoruker Ebru Esin,Özgür Emre,Keskin Metin,Ozgur Ilker,Gezer Ugur Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer. Turkish Journal of Gastroenterology, vol.32, no.9, 2021, ss.720 - 726. 10.5152/tjg.2021.20832
AMA Yoruker E,Özgür E,Keskin M,Ozgur I,Gezer U Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer. Turkish Journal of Gastroenterology. 2021; 32(9): 720 - 726. 10.5152/tjg.2021.20832
Vancouver Yoruker E,Özgür E,Keskin M,Ozgur I,Gezer U Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer. Turkish Journal of Gastroenterology. 2021; 32(9): 720 - 726. 10.5152/tjg.2021.20832
IEEE Yoruker E,Özgür E,Keskin M,Ozgur I,Gezer U "Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer." Turkish Journal of Gastroenterology, 32, ss.720 - 726, 2021. 10.5152/tjg.2021.20832
ISNAD Yoruker, Ebru Esin vd. "Fragmentation Analysis of Plasma DNA Reveals Its Prognostic Value in Gastric Cancer". Turkish Journal of Gastroenterology 32/9 (2021), 720-726. https://doi.org/10.5152/tjg.2021.20832